Researchers found for the first time that immunotherapy is significantly less effective in liver cancer patients who previously had a liver disease called non-alcoholic steatohepatitis (NASH), a growing risk factor, and in fact, using immunotherapy on NASH-related liver cancer actually appears to fuel tumour growth, according to a study published in Nature.
NASH affects as many as 40 million people worldwide and is associated to obesity and diabetes.
The researchers led a large international collaboration to investigate immunotherapy’s effect on hepatocellular carcinoma (HCC), a deadly liver cancer, caused by non-alcoholic steatohepatitis (NASH).
They conducted a meta-analysis of three randomised phase 3 trials that tested immunotherapy in HCC and found that in non-viral HCC cases, such as NASH-related HCC, therapy was significantly less effective than in viral-related cases.
In addition, this study found in animal models that immunotherapy with anti-PD1 inhibitors actually led to tumour growth instead of the intended effect of aiding the immune system to kill cancer cells and shrink the tumour.
In these models, researchers identified immune cells called CD8 PD1 as drivers of these phenomena.
“In addition to allowing clinicians to optimise treatment protocols based on the underlying liver disease, the knowledge obtained through this study will provide a backbone for the design of further combination treatments to overcome current limitations and improve survival for patients with these underlying liver conditions,” said senior and co-corresponding author Josep Llovet, MD, PhD, Founder and Director of the Liver Cancer Program at The Tisch Cancer Institute and Professor of Medicine (Division of Liver Diseases) at the Icahn School of Medicine at Mount Sinai, USA.
“These results also highlight the need for refined therapeutic strategies aimed at treating both the tumour as well as the microenvironment associated with distinct underlying liver disease.”
Non-alcoholic fatty liver disease (NAFLD), a NASH’s pre-cursor, is estimated to affect 25% of the population worldwide, and up to 20 percent of these patients will progress to having NASH.
NASH is an emerging risk factor for HCC, which led to this study’s investigation of immunotherapy’s effects on NASH-related HCC.
While immunotherapy has clinical benefit for hepatocellular carcinoma, this study’s findings are important because a quarter of all HCC patients have NASH.
The meta-analysis in this study was conducted on three, high-quality phase III trials that included more than 1,600 HCC patients treated with anti-PD1 immunotherapy.
This study represents a major international collaborative effort from 110 investigators from 81 institutions.
Source: Mount Sinai